Non-steroidal anti-inflammatory drugs—changes in prescribing may be warranted by Madhok, R. et al.
 
 
 
 
 
 
Madhok, R. and Wu, O. and McKellar, G. and Singh, G. (2006) Non-
steroidal anti-inflammatory drugs—changes in prescribing may be 
warranted. Rheumatology 45(12):pp. 1458-1460. 
 
 
 
 
 
 
 
http://eprints.gla.ac.uk/4201/ 
 
Deposited on: 30 May 2008 
 
 
Glasgow ePrints Service 
http://eprints.gla.ac.uk 
Non-steroidal anti-inflammatory drugs—changes in
prescribing may be warranted
Non-steroidal anti-inflammatory drugs (NSAIDs) are among
one of the most frequently prescribed classes of drugs. Both their
benefits and harms arise due to inhibition of cycloxygenase
(COX) of which there are two isoenzymes, COX 1 and 2.
Both COX isoenzymes have a hydrophobic tunnel, through which
the substrate accesses the active site. The tunnel is larger in
the COX 2 isoenzyme with a side pocket, a property exploited in
the development of specific COX 2 inhibitors [1]. The premise
of the initial, COX 2 hypothesis was that the gastrointes-
tinal side effects arose due to inhibition of COX 1 whereas
their anti-inflammatory or analgesic properties were COX 2
mediated. Although now appreciated to be rather naı¨ve, the
superiority of the selective COX 2 inhibitors in preventing gastro-
duodenal mucosal ulceration over the non-selective NSAIDs is
striking [2, 3].
There has been continuing scientific and media attention on
reports that selective COX 2 inhibitors increase the risk of
cardiovascular events. In an early study of major gastrointestinal
events, an unexpected 5-fold increase in the risk of acute
myocardial infarction (AMI) with rofecoxib was observed when
compared with naproxen [4]. At the time, many suggested and
aggressively pursued the hypothesis that the increased frequency
of events was a spurious observation not due to any prothrombo-
tic effects of rofecoxib, but the cardioprotective properties of
naproxen. However, subsequent placebo-controlled studies of
both rofecoxib, and celecoxib in chemoprevention also reported
an approximate 2-fold increase in cardiovascular events with
both drugs [5, 6].
More recently, attention has turned to the effects of the non-
selective NSAIDs. As aspirin confers its cardiovascular benefits
by inhibiting COX 1 [7], received wisdom has never considered
the possibility that the non-selective NSAIDs could increase the
risk of cardiovascular events. However, in February 2005,
the Food and Drugs Administration (FDA) decided to advise
that the risk of cardiovascular events for both selective COX 2
and non-selective NSAIDs is similar and has taken the step to
categorize this as a class effect [8]. In the US, all COX 2 selective
and non-selective NSAIDs now carry a black-boxed warning
on the package insert advising patients of the potential increased
cardiovascular risk [9]. The European Agency for the Evaluation
of Medicine Products (EMEA) [10] and the Medicines and
Healthcare Products Regulatory Agency (MRHA) [11] have,
however, been much more reassuring with regard to non-selective
NSAIDs and advised that ‘the data are insufficient to warrant
changes in current prescribing’.
The association between increased AMI risk and non-selective
NSAIDs has been evaluated predominantly in observational
studies [12–28]. These were primarily based on data from large
population and hospital databases that recorded the prevalence
of NSAID use combined with confirmed AMI diagnosis. While
most studies also accounted for the presence of other risk factors,
confounders and use of aspirin, few recorded the indication
and duration of NSAID use [15, 16, 18]. Overall, a general
direction of effect has been reported from the observational
studies—with the exception of one study [21], which reported
no effect between non-selective NSAID use and AMI, all
studies showed a similar trend of increased risk of AMI
compared with remote and non-use, ranging from relative risk
of 1.00 (95% CI: 0.73–1.37) [21] to 1.47 (95% CI: 1.00–2.16) [22].
Although the size of the overall relative risk appears small,
however, due to the large number of patients prescribed NSAIDs,
the absolute risk may be considerable. In addition, these studies
have presented data that suggested a differential risk between
individual NSAID such as diclofenac, naproxen and ibuprofen,
but there is insufficient evidence to conclude whether this truly
represents a class effect.
The main concern in the context of these studies is whether
the small effect observed is a real one or due to unknown or
unmeasured confounding factors, a limitation that is inherent
to all observational studies. However, such studies may be the
only feasible method to determine the potential harms of drugs
if the effects are small.
It has been advocated that the only method to resolve the
issue would be to undertake a large randomized-control trial of
non-selective NSAIDs vs placebo [29]. However, it is unlikely that
such trial would ever be funded, and it would be unethical
to randomize patients to an intervention that may be potentially
harmful.
Kearney et al. [30] have undertaken a meta-analysis of data
of vascular events from randomized-controlled trials of selective
COX 2 inhibitors. They found that in all studies selective COX 2
inhibitors increased the risk of vascular events, mainly AMI
by 42% (rate ratio 1.42; 95% CI: 1.13–1.78). Trials that compared
a COX 2 inhibitor with a traditional NSAID (n¼ 91 trials)
showed no significant difference in the risk of vascular events
(rate ratio 1.16; 95% CI: 0.97–1.38). There were no significant
differences whether all non-selective NSAIDs were considered
together, in combination, or alone when compared with COX 2
inhibitors. However, a comparison of non-selective NSAIDs
with placebo showed differences between NSAIDs—naproxen
was associated with the lowest risk (0.92; 95% CI: 0.67–1.21), but
there were insufficient data to show a cardioprotective effect;
whereas the rate ratios for ibuprofen and diclofenac were 1.51
(95% CI: 0.96–2.37) and 1.63 (95% CI: 1.12–2.37), respectively.
This study thus confirms the findings of the epidemiological
studies, but the number of cardiovascular events were small,
a limitation acknowledged by the investigators. Furthermore,
none of the comparative studies of COX 2 inhibitors with
non-selective studies were conducted in patients with high
cardiovascular risk or specifically powered to evaluate cardio-
vascular events.
The MEDAL programme and PRECISION studies are
pharmaceutical industry sponsored trials designed to address
these concerns. The MEDAL programme consists of three studies
(EDGE, EDGE II and MEDAL), and is a non-inferiority
comparison of cardiovascular events between etoricoxib and
diclofenac [31]. The EDGE studies where originally designed to
compare the gastrointestinal tolerability of etoricoxib compared
with diclofenac in osteoarthritis and rheumatoid arthritis, whereas
the MEDAL study is specifically designed to compare cardio-
vascular events in 17 804 osteoarthritis and 5700 rheumatoid
arthritis patients treated with either etoricoxib or diclofenac.
All three studies will continue until the total number of confirmed
thrombotic reaches 635 with at least 430 in the MEDAL study.
The PRECISION study is a multi-centre comparative study
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of celecoxib, diclofenac or ibuprofen coordinated by the Cleveland
Clinic which is to report in 4 yrs time [32].
Common to both non-selective NSAIDs and COX 2 inhibitors
is the adverse event of hypertension [33, 34]. Most NSAIDs
raise blood pressure by approximately 3–5mmHg [34]. Even such
a modest rise will result in a significantly increased frequency of
cardiovascular events; a 3mmHg rise in systolic blood pressure
increases the frequency of congestive cardiac failure by 10–20%,
increases the risk of stroke up to 20% and angina by 12% [35].
It has also been predicted that a 3mmHg in blood pressure in
rheumatoid arthritis patients in the US will result in an additional
21 390 ischaemic heart disease and stroke events [36]; when
extrapolated to the UK rheumatoid arthritis population, this is
equivalent to 2058 potentially avoidable fatal events.
The current evidence strongly suggests that the risk for
cardiovascular events to be similar for both non-selective
NSAIDs and COX 2 inhibitors. The potential size of the problem
is substantial. Physicians should reconsider their prescription of
non-selective NSAIDs in line with those advocated by the FDA.
Any other advice on current prescribing is unwarranted.
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